stock
AZR · ADIAL PHARMACEUTICALS, INC.
No insider buys or sales filed in 90 days; last 8-K filed Oct 28: executive or director change, bylaws or fiscal year change, shareholder vote results, regulation FD disclosure.
Price
Chart by TradingView
Members see
- Signals: which strategies fired on AZR, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- News: stories counted once across outlets
What it is
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (“AUD”). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the US and secondarily in Europe/UK.
From the 10-K for the fiscal year ended Dec 31, 2025, filed Mar 5, 2026.
Read the 10-K on SEC- Sector
- Life Sciences (SEC office)
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Employees
- Not stated in the 10-K.
- Headquarters
- Charlottesville, VA
- Incorporated in
- DE
- Fiscal year ends
- December
- Exchange
- Nasdaq
- Fractional shares
- No
- Listed options
- No
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Formerly
- Adial Pharmaceuticals, L.L.C. (until 2017); ADial Pharmaceuticals, L.L.C. (until 2017)
- Shares outstanding
- 2,625,890 as of Aug 12, 2026 (XBRL frame CY2026Q2I)
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation
Valuation ratios use the live price. Free with an account.
Start free to see thisDeep value
- NCAV
- -$88,000
- NCAV per share
- -$0.03
- NNWC
- -$221,000
- NNWC per share
- -$0.08
These figures use the live price. Free with an account.
Expectations
- Free cash flow
- —
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- —
These figures use the live price. Free with an account.
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- -27426346.1%
Health
- Current ratio
- 5.6x
- Debt/equity
- —
Trailing twelve months to Jun 30, 2026; balance sheet at Jun 30, 2026.
Growth the price implies: the yearly free cash flow growth that justifies today's value over 10 years, at a 10% discount rate, 3% growth after year 10. The market's assumption, not a forecast.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue (not reported by this company) | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| Jun 30, 2026 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$52.02M | -$51.99M | |
| Mar 31, 2026 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$2.00M | -$2.02M | Assembled from more than one filing; the filing above is only the newest of them. |
| Dec 31, 2025 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$1.89M | -$7.98T | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| Sep 30, 2025 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$1.76M | -$1.79M | |
| Jun 30, 2025 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$1.88M | -$1.96M | |
| Mar 31, 2025 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$2.27M | -$2.23M | Assembled from more than one filing; the filing above is only the newest of them. |
| Dec 31, 2024 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$1.94M | -$13.20T | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| Sep 30, 2024 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$2.21M | -$2.19M |
- Cash
- $28.71M
- Debt
- —
- Net cash
- —
- Current assets
- $28.84M
- Current liabilities
- $5.12M
- Working capital
- $23.72M
- Total liabilities
- $28.93M
- Assets
- $29.09M
- Equity
- -$38.38M
Balance as of Jun 30, 2026.
SEC data as of Nov 3, 2026
Ten years
No revenue reported in these years.
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | -$7.80M | -$7.98T | — |
| Dec 31, 2024 | — | -$8.28M | -$13.20T | — |
| Dec 31, 2023 | — | -$6.89M | -$5.12T | — |
| Dec 31, 2022 | — | -$10.86M | -$12.73M | — |
| Dec 31, 2021 | — | -$19.29M | -$19.42M | -$12.01M |
| Dec 31, 2020 | — | -$10.93M | -$10.89M | — |
| Dec 31, 2019 | — | -$8.24M | -$8.59M | — |
| Dec 31, 2018 | — | -$6.99M | -$11.63M | — |
| Dec 31, 2017 | — | -$995,286 | -$1.14M | — |
Company filings
since Tue Oct 20 · 1 offering filing in 12 months · since Fri Dec 19
events
- Executive or director changeBylaws or fiscal year changeShareholder vote resultsRegulation FD disclosure
CEO succession, abrupt
Oct 288-K - Other eventOct 168-K
- Other eventOct 28-K
- Executive or director changeShareholder vote resultsSep 188-K
- Material agreementOther eventSep 168-K
- Unregistered share saleAug 258-K
5% owners ()
Coastlands Capital LP
Stake update
Coastlands Capital LP
Passive stake
Armistice Capital, LLC
Stake update
Armistice Capital, LLC
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
No insider buys or sales filed in the last 90 days.
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Hard to borrow: Alpaca will not lend it for shorting
Off-exchange short volume, 20 days
45.1%
Through Nov 2, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
nakagai
Signals on AZR come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow AZR free
Comments · 0
No comments yet.